A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease

N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta-Analysis

(2014) Behzad Elahi et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Neurotransmitters and Microglial-Mediated Neuroinflammation

(2013) Moonhee Lee   CURRENT PROTEIN & PEPTIDE SCIENCE

Neurosteroid and neurotransmitter alterations in Parkinson’s disease

(2013) Flavia di Michele et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Unexpected Improvement in Levodopa-Induced Dyskinesia and On-Off Phenomena After Introduction of Memantine for Treatment of Parkinson's Disease Dementia

(2013) Edison I. O. Vidal et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease

(2013) Pierre Paoletti et al.   NATURE REVIEWS NEUROSCIENCE

Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones

(2013) A.R. Wild et al.   NEUROPHARMACOLOGY

NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors

(2013) X Zhou et al.   Cell Death & Disease

Mitochondrial Thiols in the Regulation of Cell Death Pathways

(2012) Fei Yin et al.   ANTIOXIDANTS & REDOX SIGNALING

Neuroprotective effect of estrogen: Role of nonsynaptic NR2B-containing NMDA receptors

(2012) Shui-bing Liu et al.   BRAIN RESEARCH BULLETIN

Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration

(2012) P Rodriguez-Rodriguez et al.   CELL DEATH AND DIFFERENTIATION

Perampanel in Parkinson Disease Fluctuations

(2012) Olivier Rascol et al.   CLINICAL NEUROPHARMACOLOGY

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

(2012) Kari Johnson et al.   CNS & Neurological Disorders-Drug Targets

Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

(2012) Susan Duty   CNS DRUGS

Therapeutic Potential of Metabotropic Glutamate Receptor Modulators

(2012) N. Hovelso et al.   Current Neuropharmacology

AMPA receptors as drug targets in neurological disease - advantages, caveats, and future outlook

(2012) Philip K.-Y. Chang et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Excitotoxicity: Bridge to various triggers in neurodegenerative disorders

(2012) Ankita Mehta et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser19

(2012) Michael F. Salvatore et al.   EXPERIMENTAL NEUROLOGY

Novel NMDA receptor modulators: an update

(2012) Rose M Santangelo et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity

(2012) Ingrid Morales et al.   GLIA

Novel Mitochondrial Targets for Neuroprotection

(2012) Miguel A Perez-Pinzon et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Effect of Oestrogen Receptors on Brain NMDA Receptors of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mice

(2012) S. Al-Sweidi et al.   JOURNAL OF NEUROENDOCRINOLOGY

Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study

(2012) C. Moreau et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Opposing Roles of Synaptic and Extrasynaptic NMDA Receptor Signaling in Cocultured Striatal and Cortical Neurons

(2012) A. M. Kaufman et al.   JOURNAL OF NEUROSCIENCE

Metabolic Changes Detected by Ex Vivo High Resolution 1H NMR Spectroscopy in the Striatum of 6-OHDA-Induced Parkinson’s Rat

(2012) Hong-Chang Gao et al.   MOLECULAR NEUROBIOLOGY

The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease

(2012) Kari A. Johnson et al.   NEUROPHARMACOLOGY

Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease

(2012) M. Amalric et al.   NEUROPHARMACOLOGY

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model

(2012) Ming-Hong Hsieh et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Impaired neurotransmission caused by overexpression of  -synuclein in nigral dopamine neurons

(2012) M. Lundblad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alpha-synuclein: from secretion to dysfunction and death

(2012) O Marques et al.   Cell Death & Disease

Kainic Acid-Induced Neurotoxicity: Targeting Glial Responses and Glia-Derived Cytokines

(2011) Xing-Mei Zhang et al.   Current Neuropharmacology

Effect of rasagiline on the molecular composition of the excitatory postsynaptic density

(2011) Fabrizio Gardoni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers

(2011) Sandra Hüls et al.   JOURNAL OF NEUROCHEMISTRY

Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease

(2011) Andrew Lees et al.   MOVEMENT DISORDERS

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Priorities in Parkinson's disease research

(2011) Wassilios G. Meissner et al.   NATURE REVIEWS DRUG DISCOVERY

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial

(2011) Hideyuki Sawada et al.   PLoS One

A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics

(2011) D Nguyen et al.   Cell Death & Disease

Oxidative Stress and Energy Crises in Neuronal Dysfunction

(2010) David G. Nicholls   Annals of the New York Academy of Sciences

Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease

(2010) Colleen M. Niswender et al.   Annual Review of Pharmacology and Toxicology

Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease

(2010) G. Ambrosi et al.   BRAIN RESEARCH BULLETIN

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

(2010) Susan Duty   BRITISH JOURNAL OF PHARMACOLOGY

Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines

(2010) Dénes Zádori et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition

(2010) V. Paille et al.   JOURNAL OF NEUROSCIENCE

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

(2010) Elisabeth Wolf et al.   MOVEMENT DISORDERS

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

(2010) Karla Eggert et al.   MOVEMENT DISORDERS

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

(2010) Giles E. Hardingham et al.   NATURE REVIEWS NEUROSCIENCE

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys

(2010) Nicolas Morin et al.   NEUROPHARMACOLOGY

Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy

(2010) Daniela Silva-Adaya et al.   NEUROTOXICOLOGY AND TERATOLOGY

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity

(2010) Diana L. Price et al.   PLoS One

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

(2009) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease

(2009) B. Greco et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Activity-dependent synaptic plasticity of NMDA receptors

(2009) Nelson Rebola et al.   JOURNAL OF PHYSIOLOGY-LONDON

NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease

(2009) Sara Varanese et al.   MOVEMENT DISORDERS

Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons

(2009) Yan-Na Wu et al.   NEUROTOXICOLOGY

Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway

(2008) Do Yeon Lee et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism

(2008) Dinesh V. Raju et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism

(2008) John G. Nutt et al.   MOVEMENT DISORDERS

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

(2007) Giovanna Levandis et al.   NEUROBIOLOGY OF DISEASE